- At 5 years, patients with localized prostate cancer treated with prostatectomy show a clinically meaningful decline in:
- Urinary function vs external beam radiation (EBRT) and low-dose-rate brachytherapy (LDR-brachytherapy) in the favorable-risk group.
- Sexual function vs EBRT+androgen deprivation therapy (ADT) in the unfavorable-risk group.
Why this matters
- These findings can help patients make informed treatment decisions.
- 2005 patients with clinically localized prostate cancer participated in a survey of patient-reported outcomes (functional outcomes and health-related QoL).
- Favorable-risk patients (n=1386) received prostatectomy, active surveillance, EBRT, or LDR-brachytherapy.
- Unfavorable-risk patients (n=619) received either prostatectomy or EBRT+ADT.
- Funding: US Agency for Healthcare Research and Quality.
- Median follow-up: 73 months.
- Favorable-risk group:
- At 5 years, nerve-sparing prostatectomy showed clinically meaningful decline in urinary incontinence vs EBRT (AMD, prostatectomy, −15.9; P<.001 and ldr-brachytherapy p>
- Urinary irritative score improved with prostatectomy vs LDR-brachytherapy (AMD, 5.4; P<.001>
- At 5 years, sexual function score declined with both treatments.
- EBRT+ADT was associated with clinically better sexual function vs prostatectomy (AMD, 12.5; P<.001>
- Survey-based study.